Particle.news
Download on the App Store
7 ARTICLES
·
last yr.

Diabetes Drug Lixisenatide Shows Promise in Slowing Parkinson's Progression

A recent study reveals that lixisenatide, a diabetes medication, may help mitigate the progression of Parkinson's disease, though side effects and the need for further research remain.

Parkinson's disease. 3D illustration showing neurons containing Lewy bodies (small red spheres) which are deposits of proteins accumulated in brain cells that cause their progressive degeneration
Image
Image
Image

Overview

  • A recent study suggests the diabetes drug lixisenatide may slow the progression of Parkinson's disease by showing no worsening of motor symptoms over 12 months compared to a placebo group.
  • The trial, involving 156 patients with early Parkinson's disease, marks a promising step in the search for treatments that can halt disease progression.
  • Lixisenatide is part of a class of drugs known as GLP-1 receptor agonists, which are also used for diabetes and obesity treatment, showing potential benefits for Parkinson's patients.
  • Nearly half of the participants experienced nausea, and 13% reported vomiting as side effects of lixisenatide.
  • Further research is needed to confirm the protective effects on the brain, determine the optimal dosage, and explore the drug's long-term benefits.